低分子肝素钙联合舒利迭吸入对慢性阻塞性肺疾病急性加重期的治疗价值

Therapeutic value of low - molecular - weight heparin calium and seretide by inhalation in patients during acute exacerbation of COPD

目的探讨低分子肝素钙与舒利迭联合吸入对慢性阻塞性肺疾病急性加重期的治疗价值。方法将诊断明确的68例病人随机分为低分子肝素钙加舒利迭（A）组和单用舒利迭（B）组，其余治疗相同，分别测试病人治疗后0、3、7d肺功能、血气分析及出凝血时间。结果A组较B组在PEF、症状计分、PaO2、PacO2等方面差异有统计学意义，P〈0．05。同组病人治疗前后差异有统计学意义，P〈0．01，A组凝血酶原时间延长小于1倍，无出血现象。结论低分子肝素钙联合舒利迭吸入治疗对慢性阻塞性肺疾病急性加重期病人安全有效。

Objective To investigate the effect of the inhalation of low -molecular -weight heparin calcium and seretide in the treatment of acute exacerbation of chronic obstructive pulmonaxy disease. Methods Sixty - eight patients diagnosed clearly divided into both low -molecular-weight heprin calcium and seretide were used （grouop A） and single seretide usde （group B）. The other drugs used in the treatment were same in each group. The pulmonaxy function ,blood gas analysis and blood coagulation time were tested at the time of 0 d ,3 d,7 d. Resuits Compared with group B,PEF,symptome scores and PaCO2 were significantly different, P 〈0.05. Compaired between before and after treatment ,there was significantly different, P 〈 0.01. In group A,prothrombin time delayed less than one time, there was no bleeding. Conclusion The inhalation treatment of the low -molecular -weight heparin calcium in the acute exacerbation of chronic obstructive pulmonaxy disease is safe and effective.